WILD-TYPE TRANSTHYRETIN AMYLOID CARDIOMYOPATHY PREDICTS THROMBOEMBOLIC RISK IN ATRIAL FIBRILLATION

The impact of wild-type transthyretin amyloid cardiomyopathy (ATTR-CA wt) on thromboembolic risk in patients with atrial fibrillation (AF) is unknown. We studied patients who underwent Tc-99m pyrophosphate scintigraphy (PYP) between 6/2015 and 6/2019. Those with positive PYP, negative serum for AL